Details for Patent: 12,178,824
Which drugs does patent 12,178,824 protect, and when does it expire?
Patent 12,178,824 protects FEMLYV and is included in one NDA.
This patent has six patent family members in six countries.
Summary for Patent: 12,178,824
| Title: | Orodispersible formulations |
| Abstract: | An orodispersible formulation for contraception or hormone replacement therapy containing an estrogen and a progestogen that has sufficient hardness, disintegration time and friability. |
| Inventor(s): | Ryan Loughlin, Roger M. Boissonneault |
| Assignee: | Millicent Pharma Ltd |
| Application Number: | US18/046,553 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; |
Drugs Protected by US Patent 12,178,824
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Millicent Mfg Pr | FEMLYV | ethinyl estradiol; norethindrone acetate | TABLET, ORALLY DISINTEGRATING;ORAL | 218718-001 | Jul 22, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,178,824
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021351921 | ⤷ Start Trial | |||
| Canada | 3194494 | ⤷ Start Trial | |||
| European Patent Office | 4221693 | ⤷ Start Trial | |||
| Japan | 2023543953 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
